The ovarian tumor-derived sEVs delivered a CRSIPR/Cas9 system editing Poly (ADP-Ribose) Polymerase-1 (PARP-1) selectively to ovarian cancer cells to increase their chemosensitivity and produced synergic cytotoxicity when combined with chemotherapy 30. Here, PARP1 is linked to ovarian cancer.